Angiogenesis: Possibilities for therapeutic interventions

Pharmacy World and Science

Volumn 20, Issue 6, 1998, Pages 225-235

  Wynendaele, W ^a   Van Oosterom, A T ^a   Pawinski, A ^a   De Bruijn, E A ^a,b,c   Maes, R A ^b  

^a Laboratory of Experimental Oncology   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Lille France   (Netherlands)

Author keywords

Angiogenesis; Cancer; Cardiovascular disease; Endothelium; Ischaemia; Wound healing

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; GENISTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HERBIMYCIN A; HYALURONIC ACID; INTERLEUKIN 2; INTERLEUKIN 8; LAVENDUSTIN A; OLEANOLIC ACID; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROLACTIN; PROLIFERIN; ROQUINIMEX; SCATTER FACTOR; SIALIC ACID DERIVATIVE; SURAMIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; URSOLIC ACID; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CARDIOVASCULAR DISEASE; DIABETIC RETINOPATHY; EMBRYO DEVELOPMENT; ENDOTHELIUM; HEART INFARCTION; ISCHEMIA; OVARY CYCLE; REVIEW; ULCER HEALING; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FORECASTING; GENE TARGETING; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032417104     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008600603059     Document Type: Review

References (131)

1. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
2. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-31.
3. Barger AC, Beeuwkes R, III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-7.
4. O'Brien ER, Garvin MR, Dev R. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883-94.
5. Stavri GT, Hong Y, Zachary IC. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995; 358: 311-5.
6. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-39.
9. Schweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359: 843-5.
10. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppress collagen arthritis. J Exp Med 1992; 175: 1135-8.
11. Nicholoff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-8.
12. Takahashi K, Mulliken JB, Kozahewich HP, Rogers RA, Kolkman J, Ezehowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93(6): 2357-64.
13. Hull MA, Cullen DJE, Hawkey CJ. Basic fibroblast growth factor in gastric ulceration: mucosal levels and therapeutic potential. Gastroenterology 1994; 106: Suppl A97. Abstract.
14. Folkman J, Szabo S, Stovroff M, Mc Neil P, Li W, Shing Y. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy which accelerates healing. Ann Surg 1991; 214: 414-27.
15. Folkman J. Angiogenesis in female reproductive organs. In: Alexander NH, d'Arrangues C, eds. Steroid hormones and uterine bleeding. Washington, DC: AAAS Press 1992; 143-58.
16. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995; 1: 27-31.
18. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine. 3rd ed Vol 1. Philadelphia: Lea & Febiger, 1993: 153-70.
19. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
20. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-31.
21. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
22. Holzman D. New view of metastasis is spreading. J Natl Cancer Inst 1996; 88: 1336-8.
23. Zhang H-T, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL, Bicknell R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor by MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995; 87:
24. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GNA, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-6.
25. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma, Int J Urol 1995; 2: 156-60.
26. Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Borachi P, Dante S, Marubini E, Harris AL. Determination of angiogenesis adds information to Estrogen receptor status in predicitng the efficacy of adjuvant tamoxifen in nodepositive breast cancer patients. Clin Cancer Res 1996; 2: 1191-8.
27. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3664-8.
28. Jensen HM, Chen I, De Vault MR, Lewis AE. Angiogenesis induced by "normal" human breast tissue: a probable marker for pre cancer. Science 1982; 218: 293-4.
29. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679-84.
30. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995; 346: 1334-5.
31. Fontanini G, Vignati S, Bigini D, Lucchi M, Mussi A, Basolo F, Angeletti CA, Bevilacqua G. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development, Int J Cancer 1996; 67: 615-9.
32. Fontanini G, Vignati S, Bigini D, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Microvessel count predicts metastatic disease and overall survival in non-small-cell lung carcinomas. J Pathol 1995; 177: 57-63.
33. Mattern J, Kallinowski F, Herfarth C, Volm M. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer, Int J Cancer 1996; 67: 20-3.
34. Lindmark G, Gerdin B, Sundberg C, Pahlman L, Bergstrom, Glimelius B. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 1996; 14: 461-6 & (reply) J Clin Oncol 1996; 14: 2402-3.
35. Lindmark G, Gerdin B, Sundberg C, Pahlman L, Bergstrom, Glimelius B. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 1996; 14: 461-6 & (reply) J Clin Oncol 1996; 14: 2402-3.
36. Pape H, Geismar D, Schmitt G. Capillar density in preirradiated breast cancer. Reg Cancer Treat 1994; 7: 118-20.
37. Astrow AB. Rethinking cancer. Lancet 1994; 343: 494-5.
38. Shipper H, Goh CR, Wang TL. Rethinking cancer; should we control rather than kill. Parts 1 & 2. Can J Oncol 1993; 3: 207-16 & 220-4.
39. Fan TPD, Jaggar R, Bichnell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16: 57-66.
40. White CW, Sonsheimer HM, Crouck EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant Interferon alfa-za. N Engl J Med 1989; 320: 1197-200.
41. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63; N Engl J Med 1994; 330: 300; & N Engl J Med 1995; 333: 595-6.
42. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63; N Engl J Med 1994; 330: 300; & N Engl J Med 1995; 333: 595-6.
43. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63; N Engl J Med 1994; 330: 300; & N Engl J Med 1995; 333: 595-6.
44. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons and down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562-6.
45. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
46. Abe J, Zhou W, Takuwa N, Taguchi J, Kurukawa K, Kumada M, Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastomagene product but not protein tyrosyl phosphorylation or proto-oncogene expression in vascular endothelial cells. Cancer Res 1994; 54: 3407-12.
47. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibtion suppresses collagen arthritis. J Exp Med 1992; 175: 1135-8.
48. Brem H and Folkman J. Analysis of Experimental Antiangiogenic therapy. J Ped Surg 1993; 28: 445-51.
49. Yazaki T, Takamiyn Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibtion of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol 1995; 23(1): 23-9.
50. Hu DE, Fan TP. Suppression of VEGF-induced angiogenesis by the protein kinase inhibitor, Lavendustin A. Br J Pharmacol 1995; 114(2): 262-8.
51. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54(10): 2654-60.
52. Presenti E, Sola F, Mongelli N, Grandi M, Spreafico F. Suramin prevents neovascularization and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992; 66(2): 367-72.
53. Pepper MS, Vasalli JD, Wilks JW, Schweigerer L, Drei L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994; 55(4): 419-34.
54. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res 1992; 52(18): 5073-5.
55. Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 1993; 32: 96-8.
56. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 2239-48.
57. Van Oosterom AT, de Smedt EA, Denis LC, de Bruijn EA, Mahler C. Surmain for prostatic cancer: a phase I/II study in advanced extensively pretreated disease. Eur J Cancer 1990: 26: 422.
58. de Bruijn EA, Pattyn G, Denis L, Mahler C, van Oosterom AT, de Smedt E. Therapeutic drug monitoring of suramin and protein binding. J Liq Chromatogr 1991; 14(20): 3719-33.
59. Braddock PS, Hu D.-E, Fan T-PD, Stratford IJ, Harris AL, Bicknell RA. A structure- activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994; 69: 890-898.
60. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta - migrating endothelial - cell - type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
61. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
62. Eisenstein R, Kuettner KE, Neopolitan C, Soble LW, Sorgente N. The resistance of certain tissues to invasion III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture. Am J Pathol 1975; 81: 337-48.
63. Brem H, Folkman J. Inhibition of tumor angiogenesismediated by cartilage. J Exp Med 1975; 141: 427-39.
64. Langer R, Conn H, Vacanti J, Haudenschild JC, Folkman J. Control of tumourgrowth in animals by infusion of an angiogenic inhibitor. Proc Natl Acad Sci USA 1980; 77: 4331-5.
65. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularisation from cartilage. Science 1990; 248: 1408-1410.
66. Moses MA, Sudhalter J, Langer R. Isolation and characterization of an inhibitor of neovescularization from scapular chondrocytes. J Cell Biol 1992; 119: 475-82.
67. Bagavandoss P, Kaytes P, Vogeli G, Wells PA and Willis JW. Recombinant truncated thrombospondin-1 monomer modulates endothelial cell plasminogen activator inhibitor 1 accumulation and proliferation in vitro. Biochem Biophys Res Commun 1990; 170: 867-72.
68. Blei F, Wilson L, Mignatti P, Rifkin D. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993; 155: 568-78.
69. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-91.
70. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982; 297: 307-12.
71. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharper KJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-9.
72. Maione TE, Gray GS, Hunt AJ, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor-4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991; 51: 2077-83.
73. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin ar a heparin fragment. Science 1985; 230: 1375-78.
74. Ingber DE, Madri J, Folkman J. A possible mechanism of inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986; 119: 1768-75.
75. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanisms of action. Ann Surg 1987; 206: 374-83.
76. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic factor -basic fibroblast growth factor- is stored within basement membrane Am J Pathol 1988; 130: 393-400.
77. Sohn K-H, Lee H-Y, Chung H-Y, Young H-S, Yi S-Y, Kim K-W. Anti-angiogenic activity of triterpene acids. Cancer Letters 1995; 94: 213-8.
78. 2. J Antibiotics 1992; 45(12): 1970-3.
79. Kretzschmar L, Metze D, Vering KH, Bonsmann G. Papillomatosis confluens et reticularis. Erfolgreiche therpaie mit minocyclin. Hautartz 1996; 47: 209-13.
80. Yamashita T, Sahai M, Kaway Y, Aino M, Takahashi K. A new activity of herbimycin A: inhibition of angiogenesis. J Antibiot 1989; 42: 1015-7.
81. Soldi R, Somavio F, Aglietta M, Primo L, Defilippi P, Marchisio PC, Bussolino F. Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Oncogene 1996; 13: 515-25.
82. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Miller NPH, Risau W, Ullrich A. High affinity VEGF binding and developmental expression suggests Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
83. Schweigerer L, Christeleit K, Fleischmann G, Adlerceutz H, Wahala K, Hase T, Schwab M, Ludwig R, Fotsis T. Identification in human urine of a natural growth inhibitor of cells derived from solid paediatric tumors. Eur J Clin Invest 1992; 22: 260-4.
84. Aldercreutz H, Hongo H, Higashi A, Fotsis Y, Hamalainen E, Okada H. Urinary excretion of lignans and isoflavoid phytoestrogens in Japanese men and women consuming a traditionel Japanese diet. Am J Clin Nutr 1991; 54: 1093-100.
85. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton N, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Sience 1997; 277: 55-60.
86. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991; 51: 2-4.
87. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell 1994; 79: 315-28.
88. Lerch OG, Rickli EE, Legier W, Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigation of the complex-forming properties. Eur J Biochem 1980; 107: 7-13.
89. Grant DS, Kleinman HK, Goldberg ID, Bhagara MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM. Scatter facror induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90: 1937-41.
90. Tsarfaty I, Resau JH, Rulang S, Keydar I, Faletto DL, Vande Woude GF. The net proto-oncogene receptor and lumen formation. Science 1992; 257: 1258-61.
91. Fotsis T, Zhang Y, Pepper MS, Aldercreutz H, Montesano R, Nauroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-239.
92. O'Shea KS, Dixit V. Unique distribution of extracellular matrix component thrombospondin in the developing mouse embryo. J Cell Biol 1988; 107: 2737-48.
93. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345-55.
94. Good DJ, Polverini RJ, Rastinejad F, Le Beau MN, Leuras RS, Frazer WA, Bouck NP. A tumor suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
95. Tolsma SS, Volpert OV, Good DJ, Frazer WA, Polverini PJ, Bouck N. Peptids from two separate domains of the matrix molecule TSP-1 have antiangiogenic activity. J Cell Biol 1993; 122: 497-511.
96. Nicosia RF, Tuszunski GP. Matrix bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994; 124: 184-93.
97. Roberts DD. Regulation of tumour growth and metastasis by thrombospondin-1. FASEB J 1996; 10: 1183-91.
98. Harning R, Koo GC, Szalay J. Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Vis Sci 1989; 30(9): 1909-15.
99. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988; 59: 44-51.
100. Norrby K. L-Proline, LACA, inhibits mast cell induced angiogenesis. Int J Microcirc Clin Exp 1993; 12: 119-29.
101. Klohs WD, Steinkampf RW, Wicha MS, Marlin AE, Tunas JB, Leopold WR. Collagen production inhibitors evaluated as antitumour-agents. JNCI/J Natl Cancer Inst 1985; 75: 353-59.
102. Lewko WM, Liotta LA, Wicha MS, Vanderhaar BK, Kidwell WR. Sensitivity of N-nitrosomethylurea-induced rat mammary tumour to cis-hydroxyproline, an inhibitor of collagen production. Cancer Res 1981; 41: 2855-62.
103. Wicha MS, Liotta LA, Lewko LA, Kidwell WR. Blocking basement membrane collagen deposition inhibits the growth of 7,12-dimethylbenzanthracene-induced rat mammary tumours. Cancer Lett 1981; 12: 9-12.
104. Tay EML, Ryhanen L, Kitto J. Proline analogues inhibit human skin fibroblasts growth and collagen production in culture. Invest Dermatol 1983; 80: 261-67.
105. Bastaki M, Missirlis E, Klouras N, Karakiulakis G, Maragoudalis E. Suppression of angiogenesis by the antitumor agent titanocene dichloride. Eur J Pharmacol 1994; 251: 263-69.
106. Majewski S, Kamisinski MJ, Szwito A, Kuminska G, Melejczk J. Inhibition of tumor induced angiogenesis by systemically administered protamine sulfates. Int J Cancer 1984; 33: 831-33.
107. Neufeld G, Gospodarowicz D. Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J Cell Physiol 1987; 132: 287-94.
108. Cockerill GW, Bert AG, Ryan GR, Gamble JR, Vadas MA, Cockerill PN. Regulation of granulocyte-macrophage colony-stimulating factor and E-selection expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 1995; 86(7): 2689-98.
109. Norrby K. Cyclosporin is angiostatic. Experienta 1992; 48: 1135-38.
110. Feinberg RN, Beebe DC. Hyaluronate in vasculogenesis. Science 1983; 220: 1177-79.
111. Belsky E, Toole BP. Hyaluronate and hyaluronidase in the developing chick embryo kidney. Cell Differ 1983; 12: 61-6.
112. Montesano R, Kumar S, Orci L, Pepper MS. Synergisti effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest 1996; 75: 249-62.
113. Lowe JB, Stoolman LM, Nair RP, Larssen RD, Berherd TC, Marks RM. ELAM-1-dependant cell adhesion to vascular endothelium determined by a transfected human fucosyl transferase cDNA. Cell (Cambridge, Mass) 1990; 63: 475-84.
114. Phillips ML, Nudelman E, Gaeta FCA, Perez M, Singhal AK, Nakomori S.-I, Paulson JC. ELAM - 1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 1990; 250: 1130-32.
115. Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 1990; 250: 1132-35.
116. Nguyen M, Folkman J, Bischoff J. 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. J Biol Chem 1992; 267: 26157-65.
117. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on CaCo-2 cells. Brit J Cancer 1997; 75: 9-16.
118. Inoue K, Korenga H, Tanaka NG, Sakamoto N, Kadoya S. The sulfated polysaccharide-peptidoglycon complex potently inhibits embryonic angiogenesis and tumour growth in the presence of cortisone acetate. Carbohydr Res 1988; 181: 135-42.
119. Tanaku NG, Sakamoto N, Korenaga H, Inoue K, Ogamura H, Osada Y. The combination of bacterial polysaccharide and tamoxifen inhibits angiogenesis and tumour growth. Int J Radiat Biol 1191; 60: 79-83.
120. Colburn P, Buonassis V. Estrogen binding sites in endothelial cell cultures. Science 1978; 201: 817-9.
121. Venkov CD, Rankin AB, Vaughan DE. Identification of authetic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94: 727-33.
122. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR, Lulahn DB, O'Donnell TF, Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor-deficient mice. Nature med 1997; 3(5): 545-8.
123. Voest EE, Kenyon BM, O'Reilly MS, Truit G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by IL-12. J Nat Cancer Inst 1995; 87(8): 581-6.
124. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by IL-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87(9): 3877-82.
125. Angiolillo AL, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by IL-12. Ann NY Acad Sci 1996; 795: 158-67.
126. Sakkoula E, Pipili-Synetos E, Mragoudakis ME. Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br J Pharmacol 1997; 122: 793-795.
127. Millauer B, Shanver LK, Plate KH, Risau W, Ulrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9.
128. Olson KA, French TC, Vallee BL, Fett JW. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 1994; 54: 4576-9.
129. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-50.
130. Kawakami-Kimura N, Narita T, Ohmori K, Yoneda T, Matsumoto K, Nakamura T, Kannagi R. Involvement of hepatocyte growth factor in increased integrin expression on HepG 2 cells triggered by adhesion to endothelial cells. Brit J Cancer 1997; 75: 47-53.
131. Horwitz AF. Integrins and health. Sci Amer 1997; May: 46-53.